Related Experiment Video

Updated: Aug 29, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance

Zhenbo Shi1,2, Jian Tu1,2, Ying Ying2,3

  • 1The Clinical Trial Research Center, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Cancers
|September 9, 2022
PubMed

Insights

CC chemokine ligand-2 (CCL2) promotes cancer development and drug resistance by affecting tumor microenvironment immunity and apoptosis. Understanding CCL2

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • CC chemokine ligand-2 (CCL2) is a key mediator of immune cell trafficking within the tumor microenvironment (TME).
  • CCL2 is increasingly recognized for its role in promoting tumor growth and progression.
  • Emerging evidence links CCL2 to resistance against various anticancer therapies.

Purpose of the Study:

  • To review the multifaceted role of CCL2 in the development of anticancer drug resistance.
  • To elucidate the underlying molecular mechanisms by which CCL2 confers resistance.
  • To highlight CCL2 as a potential therapeutic target for overcoming cancer drug resistance.

Main Methods:

  • Literature review focusing on studies investigating CCL2 and drug resistance.
  • Analysis of preclinical and clinical data on CCL2's impact on treatment efficacy.
  • Synthesis of mechanistic insights into CCL2-mediated resistance pathways.

Main Results:

  • CCL2 contributes to resistance against chemotherapy, hormone therapy, targeted therapy, and immunotherapy.
  • Mechanisms include inhibition of drug-induced apoptosis, suppression of antiangiogenesis, and modulation of antitumor immunity.
  • CCL2's influence on the TME is central to its role in promoting drug resistance.

Conclusions:

  • CCL2 is a significant factor in the development of resistance to diverse anticancer treatments.
  • Targeting CCL2 may offer a viable strategy to re-sensitize tumors to therapy.
  • Further research into CCL2 pathways is crucial for developing novel combination therapies.
Keywords:
CCL2TMEcancerdrug resistancetherapeutic target

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Chemotaxis and Direction of Cell Migration01:21

Chemotaxis and Direction of Cell Migration

Cells can detect chemical cues in their environment and reorganize the cytoskeleton to migrate toward them or away from them. This directional migration, called chemotaxis, is essential during embryogenesis and development, immune response, tissue repair and regeneration, and reproduction. These chemical cues can either attract or repel the cell's movement. For example, axon development is determined by a combination of chemoattractants and chemorepellents that direct the growing axon...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K